drugset / Trial / NCT06851962
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Phase 4
Completed
92 enrolled
Fundación para la Investigación del Hospital Clínico de Valencia
European Union · collabInstituto de Salud Carlos III · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The goal of this clinical trial is to assess the efficacy of a pharmacogenetics-guided treatment, compared to standard optimized treatment, in patients with inadequately controlled type 2 diabetes. The main questions it aims to answer are: * Is the disease better controlled when the treatment prescribed is based on the participant's pharmacogenetic profile? * What medical problems do participants experience while taking the treatment? Participants will: * Take the treatment described according to the Summary of Product Characteristics (SmPC). * Visit the clinic once every 12 weeks for checkups and tests. * Keep a diary of their symptoms to inform the Investigator.
Timeline
- Start
- 2025-05-26
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CANAGLIFLOZIN ANHYDROUS | Small molecule | — | — |
| Subject | Dapagliflozin | Small molecule | — | — |
| Subject | Dulaglutide | Peptide | — | — |
| Subject | Empagliflozin | Small molecule | — | — |
| Subject | Linagliptin | Unknown | — | — |
| Subject | Metformin | Small molecule | 2000 mg | — |
| Subject | Pioglitazone | Small molecule | — | — |
| Subject | Semaglutide | Peptide | 1 mg | — |
| Subject | Sitagliptin | Small molecule | — | — |
| Subject | Vildagliptin | Other / unclassified | — | — |